Gal Wald, MD on PROs from phase 2 gemcitabine + BCG trial in NMIBC

In an interview at the 2025 Society of Urology Oncology Annual Meeting in Phoenix, Arizona, Gal Wald, MD, highlighted patient-reported outcomes from a phase 2 trial (NCT04179162) of intravesical gemcitabine plus BCG for patients with BCG-exposed high-grade non–muscle invasive bladder cancer (NMIBC).¹

Previous data from the trial were presented in 2024, showing a complete response rate of 94% at 6 months and 81% at 12 months. Further, the 12-month high-grade recurrence-free survival was 85%.

Wald is a fifth-year urology resident at Weill Cornell Medicine in New York, New York.

REFERENCE

1. Wald G. Patient-reported outcomes in the phase II trial of intravesical gemcitabine and bacillus calmette-guerin (GemBCG) for patients with BCG-exposed high-grade non-muscle invasive bladder cancer. Presented at: Society of Urologic Oncology Annual Meeting; December 2-5, 2025; Phoenix, Arizona. Abstract 200. https://suo-abstracts.secure-platform.com/a/gallery/rounds/24/details/4794